Emily MenendeznccRCC | April 17, 2024
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
Read More
Katy MarshallnccRCC | March 29, 2024
The investigators found significant differences in OS and recurrence-free survival across the histological subtypes.
Emily MenendeznccRCC | March 14, 2024
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
Shuanzeng Wei, MD, PhDnccRCC | March 12, 2024
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
Zachary BessettenccRCC | March 11, 2024
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Elizabeth Plimack, MD, MS, FASCOAdvanced Renal Cell Carcinoma | April 1, 2024
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Katy MarshallnccRCC | January 5, 2024
Researchers noted that following first-line TKI therapy, effective subsequent treatment options for nccRCC were unclear.
Brian Rini, MD, FASCORoundtable | December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Zachary Bessette2023 IKCS: North America | March 11, 2024
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Emily MenendeznccRCC | October 19, 2023
While advances have improved understanding of molecular targets, optimal management of nccRCC remains unclear.
Emily MenendeznccRCC | September 14, 2023
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Emily MenendeznccRCC | February 5, 2024
As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for RMC.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Chung-Han Lee, MD, PhDASCO 2023 | August 23, 2023
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Zachary BessetteASCO 2023 | August 23, 2023
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | August 23, 2023
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Zachary BessetteAUA 2023 | August 23, 2023
Dr. Rini provided an overview of nccRCC, including data pertaining to response to IO monotherapy and IO/TKI combinations.
Monty Pal, MDRoundtable | August 23, 2023
The panel shares how they treat frontline papillary kidney cancer.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | August 23, 2023
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Zachary BessetteASCO GU Symposium 2023 | August 23, 2023
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.